TWIST BIOSCIENCE CORP

Twist Bioscience insiders trade strategically—selling at deep discounts, buying at premiums—showing confidence in its synthetic biology platform and future gene‑therapy revenue potential while managing liquidity.

Twist Bioscience insider sell‑to‑cover by CHESS ROBERT: 2,184 shares at $48.26—routine tax‑cover move with negligible dilution, but watch for broader executive sales during new library kit launch.

Twist Bioscience’s COO buys shares amid a 9 % weekly rally, signalling confidence in its new DNA‑synthesis platform and FDA‑cleared gene‑therapy tech – a must‑read for investors eyeing biotech upside.

Twist Bioscience insider buys signal confidence amid selling – see why Crandell Keith’s $47.51 purchase may hint at a buying opportunity near the 52‑week high.

Insider buying at Twist Bioscience sparks a brief rally—discover what directors buying near 52‑week highs could mean for investors.

Twist Bioscience’s CEO sell‑to‑cover trade reveals cash‑flow tactics, AI‑driven genomics strategy, and regulatory risks that shape its growth and investor outlook.

Explore how Twist Bioscience’s CFO insider trades reveal market perception, strategic liquidity, and future growth in synthetic DNA technology.

Twist Bioscience CFO sells shares to cover RSUs – does the 9% weekly rally signal a pullback? Explore insider trends, DNA platform strength, and investor outlook.